Mycetoma Diagnosis and Management Strategies

Mycetoma is a chronic, progressive infection of the skin and underlying tissues caused by filamentous bacteria (actinomycetoma) or fungi (eumycetoma). It presents as a painless subcutaneous mass with multiple draining sinuses that discharge characteristic grains. Early recognition is often delayed, leading to extensive local tissue damage, bone involvement and, in severe cases, deformity or amputation. Diagnosis relies on a combination of clinical examination, imaging modalities such as ultrasound and magnetic resonance imaging to define lesion extent, and laboratory techniques including direct microscopy, histopathology, culture of grains and molecular assays for accurate species identification. Each diagnostic tool varies in sensitivity, specificity and field applicability, and a multimodal approach is usually required. Management strategies depend on the causative organism: actinomycetoma responds favourably to prolonged antibacterial regimens, whereas eumycetoma often necessitates long-term antifungal therapy supplemented by surgical debridement. Current medical treatments, including itraconazole and cotrimoxazole, are hampered by suboptimal cure rates, recurrence and adverse effects. Recent efforts concentrate on novel therapeutics, combination therapies, immunomodulation and community-based interventions. A holistic, patient-centred model that integrates early case detection, tailored pharmacotherapy, minimally invasive surgery and socioeconomic support has shown promise in reducing morbidity and improving outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Mycetoma Diagnosis and Management Strategies publication trend

The graph below shows the total number of articles in mycetoma diagnosis and management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Eumycetoma: A form of mycetoma caused by true fungi, characterised by slow growth, grain formation and resistance to standard therapy.

Actinomycetoma: A bacterial mycetoma resulting from filamentous actinomycetes, often responsive to prolonged antibacterial regimens.

Grain: Microcolony of causative organisms embedded in a cement-like matrix, expelled through sinus tracts and used for laboratory identification.

IC₅₀: The concentration of a drug required to inhibit 50% of pathogen growth in vitro, indicative of potency.

Sinus tract: A narrow channel that connects a deep-seated lesion to the skin surface, through which purulent material and grains are discharged.

References

1. Mycetoma: The Spectrum of Clinical Presentation. Tropical Medicine and Infectious Disease (2018).
2. Merits and Pitfalls of Currently Used Diagnostic Tools in Mycetoma. PLOS Neglected Tropical Diseases (2014).
3. Mycetoma Medical Therapy. PLOS Neglected Tropical Diseases (2014).
4. A holistic approach to the mycetoma management. PLOS Neglected Tropical Diseases (2018).
5. Emerging therapeutics: The imidazo[1,2-b]pyridazine scaffold as a novel drug candidate for eumycetoma, a neglected tropical disease. European Journal of Medicinal Chemistry (2024).
6. Novel Compound MMV1804559 from the Global Health Priority Box Exhibits In Vitro and In Vivo Activity against Madurella mycetomatis. International Journal of Molecular Sciences (2024).
7. An update on the development of novel antifungal agents for eumycetoma. Frontiers in Pharmacology (2023).